BioAge Labs

We're pleased to share positive interim Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor being developed for patients with cardiovascular risk factors. Read the release: https://lnkd.in/gv-zGVf7 Key findings: • Well tolerated across all SAD and MAD dose levels • Convenient dosing: Pharmacokinetic profile supports once-daily oral administration • Robust target engagement: Achieved up to 98% suppression of IL-1β, a key upstream regulator of hsCRP and other inflammatory factors implicated in cardiovascular risk • High brain penetration, enabling targeting of both central and peripheral inflammation Path forward:  • We’re expanding the Phase 1 trial with additional MAD cohorts in participants with obesity and elevated cardiovascular risk factors enabling evaluation of biomarkers including hsCRP — data anticipated in 1H26  • A Phase 2a POC study focused cardiovascular risk factors in patients with obesity is anticipated to initiate in 2H26, with readout by end of year Aging biology in action: NLRP3-driven inflammation is a hallmark of aging implicated in cardiovascular disease and metabolic dysfunction, and BioAge’s discovery platform showed that reduced NLRP3 activity is associated with healthy longevity. As a brain-penetrant inhibitor with potential best-in-class properties, BGE-102 has the potential to address age-related inflammation—offering a promising approach to treating metabolic disease and reducing cardiovascular risk. We look forward to sharing additional data in 2026!

We're excited to join Longevity Global's fourth annual Longevity Summit, taking place next week December 9-10 at the Buck Institute for Research on Aging. BioAge COO and co-founder Eric Morgen, MD will deliver a keynote, and VP-Media Chris Patil, PhD will join a panel discussion on longevity in the media. We're also proud to sponsor this year's event. The Longevity Summit brings together the entire longevity ecosystem—entrepreneurs, biopharma companies, investors, researchers, and government—for two days of peer-to-peer learning focused on the business of longevity and the key areas of innovation needed to advance the field. We're honored to share the stage with so many of the leaders working to extend human healthspan. ➡️ Registration is still open: https://lnkd.in/gx8Q8mYT We look forward to seeing you there!

Last Thursday, our COO and co-founder Eric Morgen, MD spoke at the Massachusetts State House, advocating for a fundamental shift in how we approach age-related disease. 80% of adults over 65 live with at least one chronic condition, driving over $500 billion in annual healthcare costs. But how do we translate advances in the science of longevity into treatments that improve quality of life for older adults living with multiple chronic diseases? At BioAge, we're answering this question by analyzing the world's most comprehensive human aging datasets—50+ million molecular data points spanning over 50 years—to identify therapeutic targets that address root causes of metabolic disease. Our advancing clinical programs, along with multiple pharma collaborations, demonstrate how human aging biology can inform drug discovery. Massachusetts —along with the other great states investing in innovation — has an opportunity to take the lead in aging biology research. State-level life sciences funding initiatives could accelerate the translation of aging science into therapeutics that extend healthy lifespan and reduce the burden of chronic disease. Grateful to the Aging Initiative and the MA Joint Committee on Aging and Independence for organizing this briefing and creating the space for science, policy, and patient impact to converge.

The blockbuster GLP-1 medications have revolutionized treatment of obesity and diabetes, but also have potential for unprecedented impact on overall healthspan. An editorial in Nature Biotechnology asks: Could they be the first longevity drugs? They won’t be the last. Beyond GLP-1s, the editorial spotlights two promising strategies for treating chronic disease by targeting molecular mechanisms involved in human aging: blocking inflammaging by inhibiting the NLRP3 inflammasome, and activating exerkine signaling by activating the apelin receptor APJ. BioAge’s pipeline covers both strategies — an APJ agonist program spanning both oral small molecules and long-acting biologics; and BGE-102, our oral brain-penetrant NLRP3 inhibitor with best-in-class potential, currently in Phase 1 trials with initial data anticipated by year-end. We're developing therapies that target the root biology of metabolic aging to treat and prevent chronic disease — and pioneering the next generation of longevity drugs. Read the editorial: https://lnkd.in/ge7pQq89

https://lnkd.in/gcYpWabz

Our CEO Kristen Fortney keynotes the Future of Aging Research Mixer today in Cambridge, connecting with the next generation of scientists working to extend healthy lifespan through aging biology.

https://lnkd.in/gym9ErUp

Today at Longevity Biotech 2025—part of Boston Longevity Week—BioAge co-founder and COO Eric Morgen, MD, will join a panel on "Shaping the Regulatory Roadmap for Longevity Drugs." The conversation will address one of our field's most pressing challenges: navigating regulatory pathways as aging biology transitions from discovery to clinical application. Eric will share insights drawn from BioAge's experience advancing therapeutics that target the biology of human aging through clinical development for metabolic diseases. He will be joined by Alexander Fleming of the Kitalys Institute and Dylan V. Livingston of The Alliance for Longevity Initiatives. BioAge is proud to participate in this forum, which brings together biotech leaders, pharma, investors, and translational researchers to tackle the barriers facing longevity interventions—from regulatory ambiguity and biomarker validation to clinical trial design and investment landscapes. Learn more: https://lnkd.in/gbRSiU4G

Today at the 2025 Biomarkers of Aging Consortium meeting at Harvard Medical School, BioAge CEO Kristen Fortney, PhD, will share a talk entitled "Decoding Metabolic Aging: Data-Driven Paths from Human Cohorts to Biomarkers and Drug Targets." Kristen’s presentation will highlight how BioAge's discovery platform—built on over 50 million molecular measurements from longitudinal human aging data spanning five decades—identifies novel therapeutic targets by uncovering the molecular factors that maintain health as people age. BioAge is proud to sponsor this premier gathering of global leaders in geroscience, which brings together researchers, clinicians, and industry experts to advance standardized, validated biomarkers essential for evaluating the impact of longevity interventions and accelerating therapies toward the clinic. Learn more: https://lnkd.in/eE9QMHNT

WEBINAR: Today at 12 PM PT, BioAge CEO and co-founder Kristen Fortney, PhD will join experts from the academic, biotech, and public sectors in a panel discussion on the current state of existing and emerging drug interventions to extend healthspan. The event, which will be broadcast live, is hosted by the American Federation for Aging Research (AFAR) & the Academy for Health & Lifespan Research (AHLR). ➡️ Register here to tune in: https://lnkd.in/dNcaB6aS Joining Kristen on the panel will be: - Nir Barzilai, MD, Director - Institute for Aging Research, AECOM; President of AHLR  - Rafael de Cabo, PhD, Chief of the Translational Gerontology Branch of the NIA - Sara Espinoza, MD, MSc, Director of the Center for Translational Geroscience at Cedars-Sinai - Carolina Solis-Herrera MD, MD, Division Chief & Associate Professor, Division of Endocrinology, UTHealth San Antonio In a conversation moderated by Dana G Smith (Health Reporter, The New York Times) these thought leaders will: - Clarify how both repurposing existing drugs and developing novel compounds can extend healthspan - Unpack the need for human trials, the importance of an FDA indication for aging, as well as the risks in off-label use and harm of radical life extension claims - Counter myths & misinformation about longevity science - Explore how drug and lifestyle interventions work together to help us live healthier, longer We hope you’ll join us for what will surely be a fascinating discussion!